Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Personalis Inc Stock Research

PSNL

1.21USD0.00(0.00%)Delayedas of 02 Oct 2023, 11:40 am
Watchlist

Market Summary

USD1.210.00
Delayedas of 02 Oct 2023, 11:40 am
0.00%

PSNL Stock Price

PSNL RSI Chart

PSNL Valuation

Market Cap

58.7M

Price/Earnings (Trailing)

-0.53

Price/Sales (Trailing)

0.87

EV/EBITDA

0.39

Price/Free Cashflow

-0.62

PSNL Price/Sales (Trailing)

PSNL Profitability

Operating Margin

20.10%

EBT Margin

-165.58%

Return on Equity

-58.75%

Return on Assets

-41.8%

Free Cashflow Yield

-162.13%

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

67.1M

Revenue Y/Y

-8.45%

Revenue Q/Q

-11.46%

PSNL Earnings

Earnings (TTM)

-110.2M

Earnings Y/Y

13.04%

Earnings Q/Q

16.41%

Price Action

52 Week Range

1.174.31
(Low)(High)

Last 7 days

-2.4%

Last 30 days

-26.2%

Last 90 days

-35.6%

Trailing 12 Months

-58.7%

PSNL Financial Health

Current Ratio

5.35

PSNL Investor Care

Shares Dilution (1Y)

6.29%

Diluted EPS (TTM)

-2.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for PSNL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-07-31
Tachibana Aaron
sold
-1,496
2.26
-662
cfo and coo
2023-07-31
Chen Richard
sold
-1,096
2.26
-485
chief medical officer and evp
2023-06-16
Chen Richard
sold
-9,971
2.07
-4,817
chief medical officer and evp
2023-06-16
Tachibana Aaron
sold
-14,291
2.07
-6,904
cfo and coo
2023-06-16
Moore Stephen Michael
sold
-3,123
2.07
-1,509
general counsel
2023-05-17
Tachibana Aaron
sold
-2,750
1.98
-1,389
cfo and coo
2023-05-17
Chen Richard
sold
-1,922
1.98
-971
chief medical officer and evp
2023-05-17
Moore Stephen Michael
sold
-3,526
1.98
-1,781
general counsel
2023-05-02
Moore Stephen Michael
sold
-11,683
2.29
-5,102
general counsel
2023-03-17
Tachibana Aaron
sold
-11,164
2.83
-3,945
cfo and coo

1–10 of 50

Which funds bought or sold PSNL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
reduced
-40.39
-123,000
85,000
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
4.38
-4,747
11,673
-%
2023-08-15
Bragg Financial Advisors, Inc
new
-
23,771
23,771
-%
2023-08-15
GOLDMAN SACHS GROUP INC
reduced
-37.41
-119,661
88,937
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
5.75
-201
519
-%
2023-08-14
Engineers Gate Manager LP
sold off
-100
-35,720
-
-%
2023-08-14
STATE STREET CORP
unchanged
-
-114,613
244,855
-%
2023-08-14
Tower Research Capital LLC (TRC)
reduced
-66.45
-21,707
6,293
-%
2023-08-14
AMERIPRISE FINANCIAL INC
reduced
-19.83
-178,915
215,241
-%
2023-08-14
D. E. Shaw & Co., Inc.
added
2.65
-337,815
785,205
-%

1–10 of 46

Latest Funds Activity

Are funds buying PSNL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PSNL
No. of Funds

Schedule 13G FIlings of Personalis

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 31, 2023
blackrock inc.
7.7%
3,558,913
SC 13G/A
Jan 25, 2023
jpmorgan chase & co
7.6%
3,502,353
SC 13G/A
Mar 09, 2022
blackrock inc.
10.0%
4,502,224
SC 13G/A
Mar 07, 2022
lightspeed venture partners viii lp
9.16%
4,117,768
SC 13D/A
Feb 09, 2022
ark investment management llc
10.91%
4,888,115
SC 13G/A
Feb 03, 2022
blackrock inc.
9.8%
4,389,333
SC 13G/A
Jan 14, 2022
jpmorgan chase & co
9.5%
4,267,659
SC 13G/A
Feb 16, 2021
abingworth llp
0.0%
0
SC 13G/A
Feb 02, 2021
blackrock inc.
5.9%
2,309,401
SC 13G
Jan 15, 2021
jpmorgan chase & co
8.5%
3,340,089
SC 13G

Recent SEC filings of Personalis

View All Filings
Date Filed Form Type Document
Aug 28, 2023
8-K
Current Report
Aug 08, 2023
8-K
Current Report
Aug 08, 2023
10-Q
Quarterly Report
Aug 02, 2023
4
Insider Trading
Aug 02, 2023
4
Insider Trading

Peers (Alternatives to Personalis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.0B
14.7B
-12.38% 8.34%
32.87
2.45
3.86% -5.52%
32.8B
7.0B
-8.85% -8.74%
28.92
4.68
5.03% -14.68%
21.7B
4.5B
-17.33% -29.17%
-5.18
4.86
-4.92% -21931.58%
10.0B
4.2B
-6.53% 3.14%
20.76
2.4
13.29% 9.18%
MID-CAP
7.4B
1.7B
-10.66% 55.07%
27.54
4.42
30.05% 28.37%
4.5B
5.4B
1.03% -7.57%
62.57
0.82
0.01% -74.39%
SMALL-CAP
2.1B
146.1M
-25.51% 49.11%
-6.55
14.31
4.72% -55.19%
788.3M
189.6M
-20.20% -20.44%
-4.13
4.16
18.74% 17.75%
452.4M
167.5M
-15.17% -33.56%
-5.09
2.7
52.01% -99.69%
159.7M
493.9M
-38.63% -74.68%
-0.2
0.32
-1.39% 74.28%
131.9M
99.2M
7.39% -69.07%
-2.33
1.33
-26.56% -199.52%
58.7M
67.1M
-26.22% -58.70%
-0.53
0.87
-12.13% -17.68%

Personalis News

Best Stocks
Analyst Expresses Positive Outlook on Adicet Bio with 27 Price Target.
Best Stocks,
25 days ago
Business Wire

Returns for PSNL

Cumulative Returns on PSNL

-62.0%


3-Year Cumulative Returns

Risks for PSNL

What is the probability of a big loss on PSNL?

99.1%


Probability that Personalis stock will be more than 20% underwater in next one year

97.8%


Probability that Personalis stock will be more than 30% underwater in next one year.

96.4%


Probability that Personalis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PSNL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Personalis was unfortunately bought at previous high price.

Drawdowns

Financials for Personalis

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-2.2%67,139,00068,680,00065,047,00069,007,00076,410,00079,840,00085,494,00084,988,00082,543,00080,368,00078,648,00076,626,00073,963,00070,293,00065,207,00060,210,00054,711,00047,685,00037,774,00032,822,66725,926,000
  S&GA Expenses-6.0%58,840,00062,580,00063,969,00059,850,00057,209,00052,763,00047,698,00044,909,00040,562,00036,839,00033,692,00029,160,00027,423,00025,184,00022,080,00019,388,00015,990,00013,128,00011,271,00010,524,00010,416,000
  R&D Expenses2.4%65,951,00064,387,00064,912,00062,855,00061,515,00056,914,00049,312,00043,320,00036,896,00031,674,00028,568,00027,421,00025,531,00023,563,00022,418,00019,326,00017,597,00016,600,00014,304,00014,148,00014,000,000
EBITDA100.0%--104,073,000-104,642,000-95,129,000-86,666,000-74,450,000-59,014,000-52,287,333-44,249,333-38,661,000-35,463,000-28,873,000-26,313,000-22,484,000-19,194,000-16,247,000-----
EBITDA Margin100.0%--1.52-1.61-1.38-1.13-0.93-0.69-0.62-0.54-0.48-0.45-0.38-0.36-0.32-0.29-0.27-----
Interest Expenses-5.8%178,000189,000201,000213,000228,000243,000184,000166,66786,667-2,0002,000206,000951,0001,133,0001,377,0001,628,0001,456,0001,894,0002,056,0002,292,000
Earnings Before Taxes3.2%-110,105,000-113,718,000-113,275,000-102,417,000-93,594,000-81,007,000-65,212,000-58,333,000-50,215,000-44,521,000-41,223,000-34,541,000-31,885,000-28,501,000-25,075,000-21,987,000-18,742,000-20,189,000-19,879,000-21,906,000-29,256,000
EBT Margin100.0%--1.66-1.74-1.48-1.22-1.01-0.76-0.69-0.61-0.55-0.52-0.45-0.43-0.41-0.38-0.37-----
Net Income3.2%-110,174,000-113,765,000-113,315,000-102,446,000-93,624,000-81,031,000-65,226,000-58,368,000-50,243,000-44,545,000-41,280,000-34,584,000-31,924,000-28,538,000-25,084,000-21,994,000-18,750,000-20,196,000-19,886,000-21,774,666-25,380,000
Net Income Margin100.0%--1.66-1.74-1.48-1.23-1.01-0.76-0.69-0.61-0.55-0.52-0.45-0.43-0.41-0.38-0.37-----
Free Cashflow100.0%--119,661,000-120,129,000-112,680,000-97,343,000-89,720,000-81,911,000-66,429,000-63,265,000-49,362,000-45,899,000-42,038,000-37,666,000-34,276,000-26,451,000-24,411,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-8.5%24927229331835838139740738339624524914615215716019242.00
  Current Assets-11.9%16118320022226029431832935437322122412013514014017630.00
    Cash Equivalents11.5%97.0087.0089.0084.0087.0092.0010680.0070.0013769.0013325.0047.0055.0087.0016320.00
  Net PPE-3.2%59.0061.0062.0061.0048.0031.0020.0018.0014.0011.0012.0013.0013.0013.0014.0015.0013.0011.00
Liabilities-7.1%73.0079.0075.0075.0093.0094.0086.0081.0045.0047.0050.0045.0052.0053.0051.0048.0075.0059.00
  Current Liabilities-16.3%29.0034.0033.0034.0042.0040.0031.0027.0034.0039.0041.0036.0043.0052.0050.0047.0056.0058.00
Shareholder's Equity-9.1%17619421824226528731032533934819520493.0099.00107111117-
  Retained Earnings-6.2%-413-389-360-329-302-275-247-226-209-194-181-168-158-149-140-133-127-115
  Additional Paid-In Capital1.1%5895835795735695635585525485433773722522492472452449.00
Shares Outstanding3.7%49.0047.0047.0046.0046.0045.0045.0045.0044.0042.0039.0035.0032.0031.0018.0014.005.003.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations22.7%-57.69-74.62-70.23-68.74-71.86-70.44-70.83-58.09-56.33-45.75-42.65-37.72-31.23-26.78-18.07-17.27-8.064.006.00-1.726.00
  Share Based Compensation-5.1%17.0018.0019.0018.0017.0016.0014.0014.0012.0010.008.006.006.005.005.004.003.002.001.001.001.00
Cashflow From Investing-5.0%66.0069.0053.0071.0089.0019.00-60.07-163-187-147-65.14-36.85-86.43-80.65-81.58-47.40-5.42-4.77-7.85-7.78-10.47
Cashflow From Financing-3.00-1.002.001.007.00170169288284121121-20.5712113513515719.00-0.59-0.90-0.81

PSNL Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 16,699$ 18,240$ 35,559$ 33,467
Costs and expenses    
Cost of revenue11,90713,95926,03724,908
Research and development17,85216,28834,42533,386
Selling, general and administrative12,13415,87426,23131,360
Restructuring and other charges152 4,037 
Total costs and expenses42,04546,12190,73089,654
Loss from operations(25,346)(27,881)(55,171)(56,187)
Interest income1,4653492,718493
Interest expense(39)(50)(86)(109)
Other income (expense), net150(25)69
Loss before income taxes(23,919)(27,532)(52,564)(55,734)
Provision for income taxes36145021
Net loss$ (23,955)$ (27,546)$ (52,614)$ (55,755)
Net loss per share, basic$ (0.50)$ (0.60)$ (1.11)$ (1.23)
Net loss per share, diluted$ (0.50)$ (0.60)$ (1.11)$ (1.23)
Weighted-average shares outstanding, basic47,669,51345,637,83847,204,89145,316,795
Weighted-average shares outstanding, diluted47,669,51345,637,83847,204,89145,316,795

PSNL Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 97,195$ 89,128
Short-term investments40,01278,530
Accounts receivable, net10,13216,642
Inventory and other deferred costs8,1408,591
Prepaid expenses and other current assets5,4766,808
Total current assets160,955199,699
Property and equipment, net59,48661,935
Operating lease right-of-use assets24,66026,480
Other long-term assets3,9374,586
Total assets249,038292,700
Current liabilities  
Accounts payable8,84712,854
Accrued and other current liabilities16,40819,013
Contract liabilities3,3371,264
Total current liabilities28,59233,131
Long-term operating lease liabilities40,32641,041
Other long-term liabilities4,034389
Total liabilities72,95274,561
Commitments and Contingencies (Note 9)
Stockholders’ equity  
Common stock, $0.0001 par value - 200,000,000 shares authorized; 48,507,101 and 46,707,084 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively55
Additional paid-in capital589,418579,456
Accumulated other comprehensive loss(313)(912)
Accumulated deficit(413,024)(360,410)
Total stockholders’ equity176,086218,139
Total liabilities and stockholders’ equity$ 249,038$ 292,700
John S. West
330
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.